INDBInternet News Database 2.5 Updated just now · 393 sources Show or hide images Light or dark

Novartis cut its mid-term sales growth target as blockbuster patents expire

Save Like Comments Compare coverage
Image from Quartz

Summary

Peak sales guidance is higher for Kesimpta, Scemblix and Leqvio, and Novartis said its core margin is on track to return to 40% or higher by 2029

Description from Quartz.

Who is covering this

  1. Quartz Leans left Factuality: High US
    Novartis cut its mid-term sales growth target as blockbuster patents expire

    Peak sales guidance is higher for Kesimpta, Scemblix and Leqvio, and Novartis said its core margin is on track to return to 40% or higher by 2029

Comments

Comments need JavaScript.